{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:57:28Z","timestamp":1762315048844,"version":"build-2065373602"},"reference-count":20,"publisher":"Scientific Scholar","content-domain":{"domain":["cytojournal.com"],"crossmark-restriction":true},"short-container-title":["Cytojournal"],"abstract":"<jats:p>Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal neoplasms of the gastrointestinal tract and are typically associated with activating mutations in the kinase insert domain receptor (c-KIT) or platelet-derived growth factor receptor alpha. The advent of targeted therapies, such as imatinib, has substantially improved clinical outcomes; however, primary double-mutant GISTs present significant therapeutic challenges. We report the case of a 51-year-old man who presented with a 2-week history of left upper abdominal pain and melena. Contrast-enhanced abdominal computed tomography revealed a mass in the pelvic region of the small intestine. Histopathological analysis demonstrated a spindle cell morphology with a high mitotic index. Immunohistochemical staining was positive for CD117, CD34, and Dog-1, confirming the diagnosis of a high-risk small intestinal GIST. At the time of diagnosis, genetic testing was not performed, and the patient was initiated on imatinib therapy. After 5 years of treatment, the patient developed clinical resistance. First-generation sequencing identified concurrent mutations in c-KIT exons 11 (V560D) and exon 17 (N822K), implicating these double mutations in acquired imatinib resistance. This case underscores the clinical significance of double mutations in GIST, the limitations of first-line therapy in such contexts, and the importance of early genetic profiling to inform personalized treatment strategies.<\/jats:p>","DOI":"10.25259\/cytojournal_48_2025","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:53:21Z","timestamp":1762314801000},"page":"92","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent gastrointestinal stromal tumor with c-KIT double exon mutations: A rare case report"],"prefix":"10.25259","volume":"22","author":[{"given":"Ning","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Pathology, College of Basic Medical Sciences, Binzhou Medical University, Yantai, China,"},{"name":"Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second School of Clinical Medicine, Binzhou Medical University, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second School of Clinical Medicine, Binzhou Medical University, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second School of Clinical Medicine, Binzhou Medical University, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Basic Medical Sciences, Binzhou Medical University, Yantai, China,"},{"name":"Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Yantai, China,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"10.25259\/Cytojournal_48_2025\/ref-1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2559.2008.02977.x","article-title":"Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours","volume":"53","author":"Lasota","year":"2008","journal-title":"Histopathology"},{"key":"10.25259\/Cytojournal_48_2025\/ref-2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/diagnostics11020194","article-title":"Update on molecular genetics of gastrointestinal stromal tumors","volume":"11","author":"Brcic","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.25259\/Cytojournal_48_2025\/ref-3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/00003495-200767050-00012","article-title":"Imatinib: A review of its use in the management of gastrointestinal stromal tumours","volume":"67","author":"Siddiqui","year":"2007","journal-title":"Drugs"},{"key":"10.25259\/Cytojournal_48_2025\/ref-4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.25259\/Cytojournal_48_2025\/ref-5","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.25259\/Cytojournal_48_2025\/ref-6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1582-4934.2009.00983.x","article-title":"Imatinib treatment for gastrointestinal stromal tumour (GIST)","volume":"14","author":"Lopes","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.25259\/Cytojournal_48_2025\/ref-7","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.25259\/Cytojournal_48_2025\/ref-8","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.22.00294","article-title":"Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): A randomized, open-label, phase III trial","volume":"40","author":"Bauer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.25259\/Cytojournal_48_2025\/ref-9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of Helsinki: Ethical principles for medical research involving human participants","volume":"333","author":"World Medical Association","year":"2025","journal-title":"JAMA"},{"key":"10.25259\/Cytojournal_48_2025\/ref-10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000505407","article-title":"Molecular profile of gastrointestinal stromal tumors in sixty-eight patients from a single Swiss institution","volume":"87","author":"Haefliger","year":"2020","journal-title":"Pathobiology"},{"key":"10.25259\/Cytojournal_48_2025\/ref-11","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/PAS.0b013e3181ef7431","article-title":"Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size","volume":"34","author":"Rossi","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.25259\/Cytojournal_48_2025\/ref-12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/PAI.0000000000000660","article-title":"Gastrointestinal stromal tumor with multiple primary tyrosine kinase mutations-clinicopathologic and molecular characterization","volume":"27","author":"Wong","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.25259\/Cytojournal_48_2025\/ref-13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12885-023-10684-x","article-title":"Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: A single center study with review of the literature","volume":"23","author":"Yan","year":"2023","journal-title":"BMC Cancer"},{"key":"10.25259\/Cytojournal_48_2025\/ref-14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12964-023-01411-x","article-title":"KIT mutations and expression: Current knowledge and new insights for overcoming IM resistance in GIST","volume":"22","author":"Zhou","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.25259\/Cytojournal_48_2025\/ref-15","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.25259\/Cytojournal_48_2025\/ref-16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.molonc.2013.02.019","article-title":"Are two better than one? A novel double-mutant KIT in GIST that responds to imatinib","volume":"7","author":"Conca","year":"2013","journal-title":"Mol Oncol"},{"key":"10.25259\/Cytojournal_48_2025\/ref-17","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.25259\/Cytojournal_48_2025\/ref-18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/13543784.2013.740010","article-title":"Therapeutic targeting of c-KIT in cancer","volume":"22","author":"Ashman","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.25259\/Cytojournal_48_2025\/ref-19","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1111\/cas.13773","article-title":"BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor","volume":"109","author":"Tsai","year":"2018","journal-title":"Cancer Sci"},{"key":"10.25259\/Cytojournal_48_2025\/ref-20","doi-asserted-by":"publisher","first-page":"11135","DOI":"10.1021\/acs.jmedchem.9b01229","article-title":"Identification of a multitargeted tyrosine kinase inhibitor for the treatment of gastrointestinal stromal tumors and acute myeloid leukemia","volume":"62","author":"Lin","year":"2019","journal-title":"J Med Chem"}],"container-title":["Cytojournal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cytojournal.com\/recurrent-gastrointestinal-stromal-tumor-with-c-kit-double-exon-mutations-a-rare-case-report\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cytojournal.com\/recurrent-gastrointestinal-stromal-tumor-with-c-kit-double-exon-mutations-a-rare-case-report\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:53:22Z","timestamp":1762314802000},"score":1,"resource":{"primary":{"URL":"https:\/\/cytojournal.com\/recurrent-gastrointestinal-stromal-tumor-with-c-kit-double-exon-mutations-a-rare-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":20,"alternative-id":["10.25259\/Cytojournal_48_2025"],"URL":"https:\/\/doi.org\/10.25259\/cytojournal_48_2025","relation":{},"ISSN":["1742-6413","0974-5963"],"issn-type":[{"value":"1742-6413","type":"electronic"},{"value":"0974-5963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"article-number":"92"}}